NASDAQ: ONCYOncolytics Biotech Inc Stock
$0.41+0.03 (+7.89%)
Updated Nov 11, 2026
ONCY Price
$0.41
Fair Value Price
$0.05
Market Cap
$52.53M
52 Week Low
$0.37
52 Week High
$1.30
P/E
-1.2x
P/B
-8.52x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$38.13M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-2.24
Operating Cash Flow
-$27M
Beta
0.91
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ONCY Overview
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ONCY's potential to beat the market
- ONCY doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ONCY
RankedUnranked of 452
RankedUnranked of 452
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $16.52 | A | |
| $959.41 | A | |
| $419.98 | A |
Be the first to know about important ONCY news, forecast changes, insider trades & much more!
ONCY News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ONCY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ONCY ($0.41) is overvalued by 780.28% relative to our estimate of its Fair Value price of $0.05 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ONCY ($0.41) is not significantly undervalued (780.28%) relative to our estimate of its Fair Value price of $0.05 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ONCY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ONCY due diligence checks available for Premium users.
Valuation
ONCY fair value
Fair Value of ONCY stock based on Discounted Cash Flow (DCF)
Price
$0.41
Fair Value
$0.05
Overvalued by
776.01%
ONCY ($0.41) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ONCY ($0.41) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ONCY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ONCY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.2x
Industry
17.04x
Market
42.33x
ONCY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-8.52x
Industry
5.31x
ONCY's financial health
Profit margin
Revenue
$0.0
Net Income
-$9.4M
Profit Margin
0%
ONCY's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$7.7M
Liabilities
$13.8M
Debt to equity
-2.24
ONCY's short-term assets ($7.07M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ONCY's long-term liabilities ($8.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ONCY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ONCY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.1M
Investing
$0.0
Financing
$6.8M
ONCY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ONCY vs Biotech Stocks
Oncolytics Biotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.